145,980 Shares in Revvity, Inc. (NYSE:RVTY) Bought by Universal Beteiligungs und Servicegesellschaft mbH

Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in Revvity, Inc. (NYSE:RVTY - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 145,980 shares of the company's stock, valued at approximately $16,293,000. Universal Beteiligungs und Servicegesellschaft mbH owned 0.12% of Revvity as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently modified their holdings of RVTY. T. Rowe Price Investment Management Inc. raised its holdings in shares of Revvity by 16.7% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 20,761,308 shares of the company's stock worth $2,317,170,000 after buying an additional 2,969,326 shares during the period. EdgePoint Investment Group Inc. increased its holdings in Revvity by 51.1% during the 4th quarter. EdgePoint Investment Group Inc. now owns 4,058,231 shares of the company's stock worth $452,939,000 after purchasing an additional 1,372,456 shares during the period. Price T Rowe Associates Inc. MD increased its holdings in Revvity by 17.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,631,597 shares of the company's stock worth $851,764,000 after purchasing an additional 1,151,821 shares during the period. Norges Bank purchased a new position in Revvity during the 4th quarter worth $127,801,000. Finally, Invesco Ltd. increased its holdings in Revvity by 18.8% during the 4th quarter. Invesco Ltd. now owns 1,740,933 shares of the company's stock worth $194,306,000 after purchasing an additional 274,923 shares during the period. 86.65% of the stock is currently owned by hedge funds and other institutional investors.

Revvity Stock Up 1.9%

Shares of NYSE:RVTY traded up $1.72 on Tuesday, reaching $91.04. The company had a trading volume of 927,607 shares, compared to its average volume of 952,783. Revvity, Inc. has a 52-week low of $87.70 and a 52-week high of $129.50. The firm's 50 day simple moving average is $94.33 and its 200-day simple moving average is $107.84. The firm has a market capitalization of $10.73 billion, a PE ratio of 41.19, a PEG ratio of 3.82 and a beta of 1.02. The company has a current ratio of 3.60, a quick ratio of 3.03 and a debt-to-equity ratio of 0.41.

Revvity (NYSE:RVTY - Get Free Report) last announced its earnings results on Monday, April 28th. The company reported $1.01 earnings per share for the quarter, topping the consensus estimate of $0.96 by $0.05. Revvity had a return on equity of 7.68% and a net margin of 9.81%. The firm had revenue of $664.76 million for the quarter, compared to the consensus estimate of $662.30 million. During the same period in the previous year, the business earned $0.98 EPS. The firm's revenue for the quarter was up 2.3% on a year-over-year basis. As a group, analysts expect that Revvity, Inc. will post 4.94 earnings per share for the current fiscal year.

Revvity Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 8th. Investors of record on Friday, July 18th will be paid a dividend of $0.07 per share. The ex-dividend date is Friday, July 18th. This represents a $0.28 annualized dividend and a yield of 0.31%. Revvity's dividend payout ratio (DPR) is 11.91%.

Analyst Upgrades and Downgrades

RVTY has been the topic of several research reports. Raymond James restated an "outperform" rating and set a $120.00 price objective (down from $145.00) on shares of Revvity in a report on Tuesday, April 29th. Wall Street Zen downgraded Revvity from a "buy" rating to a "hold" rating in a report on Saturday, May 24th. JPMorgan Chase & Co. reduced their price objective on Revvity from $120.00 to $100.00 and set a "neutral" rating on the stock in a report on Tuesday, April 29th. The Goldman Sachs Group reduced their price objective on Revvity from $140.00 to $125.00 and set a "buy" rating on the stock in a report on Tuesday, April 29th. Finally, KeyCorp raised their price objective on Revvity from $132.00 to $145.00 and gave the stock an "overweight" rating in a report on Monday, February 3rd. Five equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Revvity presently has an average rating of "Moderate Buy" and an average price target of $125.64.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.